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CXCL1 – in the study of Ferwerda a signal for association with dis-
ease susceptibility – has been implicated in a wide range of neuropa-
thologies including a role in neuroinﬂammation (Semple et al., 2010).
As a neutrophil chemoattractant being synthesized by activatedmicrog-
lia, astrocytes, and endothelial cells it is of particular interest in the path-Pneumococcal meningitis is a relevant world-wide problem with
~1.000,000 cases within the last 20 years, 80,000 alone in 2009 (Global
Healthy Observatory Data of theWorld Health Organization). Pneumo-
coccal meningitis causes the highest mortality rates of all meningitis-
causing bacterial pathogens and the highest rates of severe disabling
neurological sequelae (Schut et al., 2012; van de Beek et al., 2012; van
de Beek et al., 2004).
Invasion of the subarachnoid space by Streptococcus pneumoniae
causes a strong inﬂammatory cascade orchestrated by the innate im-
mune system involving several receptors like Toll-like receptors (TLR)
as well as various cytokines and chemokines (Hanke and Kielian,
2011). It is an important question whether genetic variations of the in-
nate immune genes alter the immune response and thereby inﬂuence
the susceptibility and outcome of bacterial meningitis. In this issue of
EBioMedicine, Ferwerda and colleagues (Ferwerda et al., 2016) assumed
this task and conducted a sequencing study within the coding se-
quences and ﬂanking intronic regions of 46 innate immune genes in a
unique Dutch patient population of 435 patients with community-ac-
quired pneumococcal meningitis and 416 controls (partners or non-re-
lated proxies, living in the same residence) to determine the impact of
genetic variation of innate immune response genes on pneumococcal
meningitis susceptibility and disease severity. The authors identiﬁed
variations in chemokine (C-X-Cmotif) ligand 1 (CXCL1) and Caspase re-
cruitment domain family, member 8 (CARD8) genes as the strongest
candidates associated with susceptibility while variations within the
Nucleotide-binding oligomerization domain containing 2 (NOD2) and
Interleukin-1 receptor-associated kinase 4 (IRAK4) genes were associ-
ated with disease outcome. However, it is of note that after correctionom.2016.07.011.
ndenburg).
. This is an open access article underfor multiple testing none of the variation signals including previous
published variants reached statistical signiﬁcance.
ogenesis of bacterialmeningitis and could explain the context of disease
susceptibility. It could be a target candidate for further studies investi-
gating its inﬂammation-modulating properties. Furthermore, CCL2
being related to CXCR2 with its ligand CXCL1 plays a role in adult
neurogenesis. Hippocampal neurogenesis as a regenerating impulse to
alleviate neuronal damage is being upregulated after bacterial meningi-
tis (Gerber et al., 2009). Therefore, next to regulating inﬂammation by
altering and accelerating immune cell trafﬁcking, CXCL1 may be in-
volved in regenerative properties, something that demands further in-
vestigation with the knowledge of the present study.
The strongest signal associated with the outcome after pneumococ-
cal meningitis was IRAK4 which is a downstream TLR or IL-1 receptor
superfamily signaling protein that is essential to trigger innate immune
actions. IRAK4 deﬁciency leads to inhibition of TLR signaling as well as
defective immune responses to IL-1 and IL-8 and causes increased sus-
ceptibility to bacteria in children (Picard et al., 2003). IRAK4-deﬁciency
is further known as a cause of recurrent pneumococcal infection (Picard
et al., 2010) which is of particular importance in the present context of
pneumococcal meningitis.
Scientiﬁc limitations of the study are the focus on variations located
within the protein coding regions so that genetic variations near the
genes involved in transcription regulation are being missed. This could
be of particular importance since variations of expression of relevant in-
ﬂammatory mediators such as TLR and chemokines cannot be taken
into account under these circumstances. Furthermore, the missing dis-
crimination between the different pneumococcal strains might be of
disadvantage. From a clinical point of view, the interpretation of the
data is limited because of lacking data concerning the time point of di-
agnosis after onset of symptoms as well as the starting time point of an-
tibiotic treatment and the kind of antibiotic – all these factors having
major impact on disease severity and outcome in general.
Excessive inﬂammatory responses are harmful for neuronal tissue
and impair the outcome after meningitis (Mook-Kanamori et al.,
2011). The duration and severity of inﬂammation are also crucial forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tempts to regulate, attenuate and shorten the inﬂammatory response
during bacterial meningitis have long been and still remain a major tar-
get for studies with adjuvant therapeutic agents. So far, only the adju-
vant therapy with dexamethasone became part of the therapy
guidelines of bacterial meningitis in the Western world in cases with
suspected or proven pneumococcal meningitis but not meningococcal
meningitis. However, the application of dexamethasone has remained
somewhat ambiguous as some studies detected no beneﬁt or experi-
mental studies even showed a decrease in learning ability after pneu-
mococcal meningitis (Mook-Kanamori et al., 2011). Therefore, new
therapeutic approaches are most wanted. The signiﬁcance of IRAK4 as
the most promising candidate of this study concerning disease severity
and outcome should be further investigated as an adjuvant therapy
combinedwith the established antibiotic regime used every day in clin-
ical practice.
In summary, Ferwerda and colleagues (Ferwerda et al., 2016) pres-
ent important insight in the role of genetic variations of the innate im-
mune system in pneumococcal meningitis and contribute to a better
understanding of the complexity of the innate immune response in
pneumococcal meningitis.
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